Feng Liu, George Boon‐Bee Goh, Dina Tiniakos, Aileen Wee, Wei‐Qiang Leow, Jing‐Min Zhao, Hui‐Ying Rao, Xiao‐Xiao Wang, Qin Wang, Wei‐Keat Wan, Kiat‐Hon Lim, Manuel Romero‐Gomez, Salvatore Petta, Elisabetta Bugianesi, Chee‐Kiat Tan, Stephen A. Harrison, Quentin M. Anstee, Pik‐Eu Jason Chang, Lai Wei – 10 October 2019
The systematic screening for NAFLD is currently not recommended by the AASLD practice guidelines although the presence of type 2 diabetes is a known risk factor for the progression of NAFLD towards NASH and advanced fibrosis. This webinar will discuss the pros and cons for the systematic screening of NAFLD-related advanced fibrosis in patient with type 2 diabetes.
Emanuele Felli, Antonio Saviano, Simona Tripon, Thomas F. Baumert, Patrick Pessaux – 9 October 2019
Rohit Nathan, Deepanshu Jain, Simona Rossi – 9 October 2019
Salvatore Piano, Paolo Angeli – 9 October 2019
Guadalupe Garcia‐Tsao – 9 October 2019
Edoardo Poli, Ilias Kounis, Catherine Guettier, Céline Verstuyft, Audrey Coilly, Rodolphe Sobesky, Cyrille Feray, Eric Vibert, Oriana Ciacio, Didier Samuel, Henri Bismuth, Jean‐Charles Duclos‐Vallée – 9 October 2019
Edoardo Poli, Ilias Kounis, Catherine Guettier, Céline Verstuyft, Audrey Coilly, Rodolphe Sobesky, Cyrille Feray, Eric Vibert, Oriana Ciacio, Didier Samuel, Henri Bismuth, Jean‐Charles Duclos‐Vallée – 9 October 2019
Hani M. Wadei, Peter Abader, Ali A. Alsaad, Kristopher Croome, Cherise Cortese, Xochiquetzal J. Geiger, Samir Khouzam, Martin L. Mai, C. Burcin Taner, Andrew P. Keaveny – 9 October 2019 – Renal dysfunction is common in liver transplantation (LT) candidates, but differentiating between reversible and irreversible renal injury can be difficult. Kidney biopsy might be helpful in differentiating reversible from irreversible renal injury, but it is associated with significant complications.
Gyongyi Szabo – 9 October 2019